03:46 PM EST - Trimel Pharmaceuticals Corporation : announced that the New Drug Application for its bioadhesive intranasal gel testosterone product has been formally accepted for review by the United States Food and Drug Administration. The NDA is supported by efficacy and safety results from 306 patients who participated in the pivotal Phase III study. Trimel Pharmaceuticals Corporation
shares T.TRL are trading unchanged at $0.72.
